原发性肝细胞癌患者血清酸性同工铁蛋白水平的观察

Observation of the Serum Acidic Isoferritin Levels in Patients with Hepatocellular Carcinoma

为探讨酸性同工铁蛋白对原发性肝癌（ＨＣＣ）的临床价值，采用ＥＬＩＳＡ－双抗体夹心法，测定４８例ＨＣＣ、３０例肝炎（ＨＰ）、２８例肝硬化（ＬＣ）患者及３３例正常人血清酸性同工铁蛋白（ＳＡＩＦ）水平。结果显示：ＨＣＣ、ＨＰ和ＬＣ组患者ＳＡＩＦ值均呈现非正态分布，其中位值分别为４４０μｇ／Ｌ、２１８μｇ／Ｌ和１２０μｇ／Ｌ，正常组为６６μｇ／Ｌ。ＨＣＣ组与其余各组比较，有显著性差异（Ｐ＜０．０５，Ｐ＜０．０１，Ｐ＜０．０１）ＨＰ与ＬＣ组和正常组比较，其差异也有显著性（Ｐ＜０．０５），但ＬＣ组与正常组比较则无显著性差异（Ｐ＞０．０５）。用ＲＯＣ确定ＳＡＩＦ＝２５０μｇ／Ｌ为临界值，则ＳＡＩＦ诊断ＨＣＣ的阳性率为８５．４６％。ＳＡＩＦ与ＡＦＰ无相关性。ＳＡＩＦ与肝癌体积和临床分期无关。

The levels of serum acidic isoferritin (SAIF) in 48 patients with hepatocellular carcinoma(HCC),30 patients with hepatitis,28 patients withliver cirrihosis,and 33 healthy subjects were measured by using enzymelinked immunosorbent assay(ELISA——doubledeterminant.The result revealed that the SAIF values of HCC,HP and LC did not show normal distribution.The median values were 440μg/L,21μg/L,120μg/L and,in normal subjects,66μg/L respectively.There were statistically significant differences between HCC and the control groups.The sensitivity of SAIF to HCC was 85.46%,with the cutoff point being 250μg/L.SAIF was not correlated to AFP in HCC cases.The values of SAIF had no relationship with the volume of the tumors and the clinical stages.SAIF may be an available and useful serum marker and be beneficial to the diagnosis of earlystaged HCC.